Replimune Group Inc (REPL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Replimune Group Inc (REPL) has a cash flow conversion efficiency ratio of -0.313x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.95 Million) by net assets ($210.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See REPL equity financing ratio to measure how much of total assets are equity-financed.
Replimune Group Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Replimune Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Replimune Group Inc to assess how comfortably operating cash covers total debt obligations.
Replimune Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Replimune Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anteris Technologies Global Corp. Common Stock
NASDAQ:AVR
|
-0.103x |
|
Shanghai Chuangli Group Co Ltd
SHG:603012
|
0.010x |
|
Adlai Nortye Ltd. American Depositary Shares
NASDAQ:ANL
|
1.705x |
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
CSBC Corp Taiwan
TW:2208
|
-0.623x |
|
Doosan Skoda Power as
PR:DSPW
|
N/A |
|
Westlake Chemical Partners LP
NYSE:WLKP
|
0.139x |
|
PHARMING GRP SP. ADRS
F:PHG
|
0.039x |
Annual Cash Flow Conversion Efficiency for Replimune Group Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Replimune Group Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Replimune Group Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $415.84 Million | $-192.25 Million | -0.462x | +6.65% |
| 2024-03-31 | $374.51 Million | $-185.47 Million | -0.495x | -114.76% |
| 2023-03-31 | $555.29 Million | $-128.05 Million | -0.231x | -15.39% |
| 2022-03-31 | $411.23 Million | $-82.18 Million | -0.200x | -62.35% |
| 2021-03-31 | $498.73 Million | $-61.39 Million | -0.123x | +62.65% |
| 2020-03-31 | $183.72 Million | $-60.55 Million | -0.330x | -79.04% |
| 2019-03-31 | $137.86 Million | $-25.38 Million | -0.184x | -132.27% |
| 2018-03-31 | $-28.07 Million | $-16.01 Million | 0.571x | -7.17% |
| 2017-03-31 | $-11.52 Million | $-7.08 Million | 0.615x | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more